Letrozole
Metastatic Colon Cancer
University of Rome Tor VergataSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Metastatic Colon Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fruquintinib Peking University | Phase 3 | BBB |
Adebrelimab Sapience Therapeutics | Phase 3 | BB |
Cetuximab Shanghai 6th People's Hospital | Phase 3 | BB |
PANITUMUMAB University of Campania Luigi Vanvitelli | Phase 2 | BB |
Nivolumab Massachusetts General Hospital | Phase 3 | B |
View all 28 →
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →